Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Pharming Group NV (PHARM) Ordinary EUR0.01

Sell:€0.81 Buy:€0.83 Change: €0.0086 (1.06%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
Change: €0.0086 (1.06%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
Change: €0.0086 (1.06%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

Contact details

Darwinweg 24
2333 CR
+31 (71) 5247400

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€523.97 million
Shares in issue:
646.12 million
Euronext Amsterdam

Key personnel

  • Sijmen de Vries
    Chief Executive Officer, Executive Director
  • Jeroen Wakkerman
    Chief Financial Officer
  • Mireille Sanders
    Chief Operations Officer
  • Robert Friesen
    Chief Scientific Officer
  • Anne-Marie de Groot
    Chief Ethics and Compliance Officer
  • Stephen Toor
    Chief Commercial Officer and General Manager - Americas
  • Anurag Relan
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.